Skip to main content
Clinical Trials/EUCTR2019-004455-36-FR
EUCTR2019-004455-36-FR
Active, not recruiting
Phase 1

Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients. - ATO-TS

CHU DE POITIERS0 sites45 target enrollmentNovember 26, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
CHU DE POITIERS
Enrollment
45
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 26, 2019
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients: Tourette’s patients from 10 to 35 years old diagnosed according to the criteria of DSM\-V, with high impulsive trait, and who freely consent to this study
  • Healthy subjects, of normal development, free from any neuropsychiatric pathology, matched 1:1 in age and sex to the patients recruited in this study.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 20
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Other psychiatric disease of the axis I of DSM\-IV, severe depression, allergic reactions to chemical coumpounds of the treatment or medical contraindications of atomoxetine, concommitent treatments contraindicated with atomoxetine (IMAO) interrupted from less tha 2 weeks or Clonidine or Methyphenidate interrupted from less than 1 month

Outcomes

Primary Outcomes

Not specified

Similar Trials